Sugi Predict

Sugi Predict / Compounds / SCHEMBL237029

SCHEMBL237029

SCHEMBL237029

CC(C)(C)OC(=O)N(CC(=O)O)C1CC1c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 5/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ MAOA P21397 1/20 0.44
▸ MAOB P27338 1/20 0.42
▸ RORC P51449 1/20 0.40
▸ SIGMAR1 Q99720 1/20 0.38
▸ HSD11B1 P28845 1/20 0.37
▸ TLR2 O60603 1/20 0.36
▸ TLR1 Q15399 1/20 0.36
▸ GPR88 Q9GZN0 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ TACR1 P25103 1/20 0.35
▸ HRH3 Q9Y5N1 1/20 0.35
▸ ABCB1 P08183 1/20 0.35
▸ EZH2 Q15910 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL237030 1.00 KDM1A (0.46) KDM1AHDAC8HDAC6MAOAMAOB
SCHEMBL2755941 1.00 KDM1A (0.46) KDM1AHDAC8HDAC6MAOAMAOB
SCHEMBL19584853 0.89 KDM1A (0.58) KDM1AHDAC8HDAC6MAOAMAOB
SCHEMBL12242253 0.89 MAOA (0.44) KDM1AHDAC8HDAC6MAOAMAOB
SCHEMBL12242254 0.82 KDM1A (0.43) KDM1AHDAC8HDAC6MAOAMAOB
SCHEMBL19609403 0.82 KDM1A (0.42) KDM1AHDAC8HDAC6MAOAMAOB
SCHEMBL19091688 0.82 KDM1A (0.45) KDM1AHDAC8HDAC6MAOAMAOB
SCHEMBL22629316 0.82 KDM1A (0.43) KDM1AHDAC8HDAC6MAOAMAOB
SCHEMBL19025233 0.82 KDM1A (0.45) KDM1AHDAC8HDAC6MAOAMAOB
SCHEMBL19025234 0.82 KDM1A (0.45) KDM1AHDAC8HDAC6MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479797-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors Jubilant Epicore LLC (US) 2025-11-25 — — US disclosed
EP-3455204-B1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS Jubilant Epicore LLC (US) 2025-10-29 — — EP disclosed
US-20220281815-A1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS Jubilant Epicore LLC 2022-09-08 — — US disclosed
US-11352322-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors Jubilant Epicore LLC (US) 2022-06-07 — — US disclosed
CN-109153636-B Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors 朱比连特埃皮科尔有限责任公司 2021-10-22 — — CN disclosed
US-20200308110-A1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS Jubilant Epicore LLC 2020-10-01 — — US disclosed
EP-2486002-B1 SUBSTITUTED HETEROARYL- AND ARYL- CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE ORYZON GENOMICS SA (ES) 2019-03-27 — — EP disclosed
EP-3455204-A1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS Jubilant Biosys Ltd. (IN) 2019-03-20 — — EP disclosed
CN-109153636-A Cyclopropyl-amide compound as dual LSD1/HDAC inhibitor 朱比连特比利斯有限公司 2019-01-04 — — CN disclosed
WO-2017195216-A1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2017-11-16 — — WO disclosed
US-20160045456-A1 PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE ORYZON GENOMICS S.A. (ES) 2016-02-18 — — US disclosed
US-8993808-B2 Phenylcyclopropylamine derivatives and their medical use ORYZON GENOMICS, S.A. (ES) 2015-03-31 — — US disclosed
US-8946296-B2 Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use ORYZON GENOMICS S.A. (ES) 2015-02-03 — — US disclosed
US-20120264823-A1 SUBSTITUTED HETEROARYL- AND ARYL-CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE ORYZON GENOMICS S.A. 2012-10-18 — — US disclosed
US-20120004262-A1 PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE ORYZON GENOMICS, S.A. (ES) 2012-01-05 — — US disclosed
EP-2389362-A1 PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE Oryzon Genomics, S.A. (ES) 2011-11-30 — — EP disclosed
US-20110252680-A1 Surface mounted frame arrangement ROSE DISPLAYS, LTD 2011-10-20 — — US disclosed
WO-2010084160-A1 PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE ORYZON GENOMICS S.A. (ES) 2010-07-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200308110-A1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS HDAC1, HDAC11, HDAC2 KDM1A 13/4885HDAC8 9/4885HDAC6 8/4885
US-11352322-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors HDAC1, HDAC11, HDAC2 KDM1A 13/4885HDAC8 9/4885HDAC6 8/4885
US-20120264823-A1 SUBSTITUTED HETEROARYL- AND ARYL-CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE CBR1, CNR1, CBR3 KDM1A 877/4885HDAC8 3224/4885HDAC6 933/4885
US-12479797-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors HDAC1, HDAC11, HDAC2 KDM1A 15/4885HDAC8 10/4885HDAC6 7/4885
US-20120004262-A1 PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE PNMT, ABCB1, SNCA KDM1A 1515/4885HDAC8 2501/4885HDAC6 541/4885
US-20220281815-A1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS HDAC1, HDAC11, HDAC2 KDM1A 15/4885HDAC8 10/4885HDAC6 7/4885
US-20160045456-A1 PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE PNMT, ABCB1, SNCA KDM1A 1515/4885HDAC8 2501/4885HDAC6 541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.